Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 15/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.34 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15727499 | 0.83 | IRAK4 (0.39) | IRAK4GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL21180014 | 0.83 | IRAK4 (0.39) | IRAK4GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL5215591 | 0.79 | IRAK4 (0.37) | IRAK4GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL9865629 | 0.79 | IRAK4 (0.37) | IRAK4GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL9865753 | 0.79 | — | — | |
| SCHEMBL12409742 | 0.79 | — | — | |
| SCHEMBL12459955 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL27036387 | 0.77 | IRAK4 (0.39) | IRAK4PDK2IRAK1 | |
| Hydrochloric Acid SCHEMBL30683992 | 0.77 | IRAK4 (0.39) | IRAK4PDK2IRAK1 | |
| SCHEMBL1715768 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242105-B2 | Structural mimetics of proline-rich peptides and the pharmaceutical use thereof | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2012-08-14 | — | — | US | disclosed |
| US-20110034438-A1 | STRUCTURAL MIMETICS OF PROLINE-RICH PEPTIDES AND THE PHARMACEUTICAL USE THEREOF | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2011-02-10 | — | — | US | disclosed |
| WO-2008040332-A1 | STRUCTURAL MIMETICS OF PROLINE-RICH PEPTIDES AND THE PHARMACEUTICAL USE THEREOF | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034438-A1 | STRUCTURAL MIMETICS OF PROLINE-RICH PEPTIDES AND THE PHARMACEUTICAL USE THEREOF | PRNP, PRAP1, LRPPRC | IRAK4 2420/4885GABRA1 2347/4885GABRG2 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.